What is Barclays's price target for RAPT?

Barclays's latest stated price target for RAPT Therapeutics Inc. (RAPT) is $35, from its action on Oct 13, 2025.

What is Barclays's rating on RAPT?

Barclays rates RAPT Overweight, a bullish rating, as of Oct 13, 2025.

When did Barclays last change its view on RAPT?

On Oct 13, 2025, Barclays starts coverage at Overweight, price target $35.

Barclays RAPT price target and rating history

RAPT Therapeutics Inc. (RAPT) · Health Care

Barclays rates RAPT Therapeutics Inc. (RAPT) Overweight with a $35 price target, as of its latest action on Oct 13, 2025. It has published 3 rating actions on RAPT since June 2023, including 0 upgrades and 1 downgrade.

Current rating: Overweight
Price target: $35
Median target, all firms: Too few
Actions on RAPT: 3

Barclays price target on RAPT

Barclays price target on RAPT, each point a stated target, June 2023 to October 2025.

Every Barclays rating on RAPT

Oct 13, 2025
InitiateBarclays starts coverage at Overweight, price target $35
May 10, 2024
DowngradeBarclays downgrades to Equal Weight from Overweight, price target $13 to $4
Jun 15, 2023
InitiateBarclays starts coverage at Overweight, price target $35

Questions about Barclays and RAPT

What is Barclays's price target for RAPT?: Barclays's latest stated price target for RAPT Therapeutics Inc. (RAPT) is $35, from its action on Oct 13, 2025.
What is Barclays's rating on RAPT?: Barclays rates RAPT Overweight, a bullish rating, as of Oct 13, 2025.
When did Barclays last change its view on RAPT?: On Oct 13, 2025, Barclays starts coverage at Overweight, price target $35.

More RAPT rating histories

All Barclays ratings RAPT news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.